Literature DB >> 24138309

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.

Courtney D DiNardo1, Keyur P Patel, Guillermo Garcia-Manero, Rajyalakshmi Luthra, Sherry Pierce, Gautam Borthakur, Elias Jabbour, Tapan Kadia, Naveen Pemmaraju, Marina Konopleva, Stefan Faderl, Jorge Cortes, Hagop M Kantarjian, Farhad Ravandi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24138309      PMCID： PMC4139917          DOI： 10.3109/10428194.2013.855309

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  26 in total

1.  Identification of a gene, MLL, that spans the breakpoint in 11q23 translocations associated with human leukemias.

Authors:  S Ziemin-van der Poel; N R McCabe; H J Gill; R Espinosa; Y Patel; A Harden; P Rubinelli; S D Smith; M M LeBeau; J D Rowley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-01       Impact factor: 11.205

2.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

Authors:  Klaus H Metzeler; Heiko Becker; Kati Maharry; Michael D Radmacher; Jessica Kohlschmidt; Krzysztof Mrózek; Deedra Nicolet; Susan P Whitman; Yue-Zhong Wu; Sebastian Schwind; Bayard L Powell; Thomas H Carter; Meir Wetzler; Joseph O Moore; Jonathan E Kolitz; Maria R Baer; Andrew J Carroll; Richard A Larson; Michael A Caligiuri; Guido Marcucci; Clara D Bloomfield
Journal:  Blood       Date:  2011-10-26       Impact factor: 22.113

3.  Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellström-Lindberg; Valeria Santini; Norbert Gattermann; Ulrich Germing; Guillermo Sanz; Alan F List; Steven Gore; John F Seymour; Hervé Dombret; Jay Backstrom; Linda Zimmerman; David McKenzie; C L Beach; Lewis R Silverman
Journal:  J Clin Oncol       Date:  2009-12-21       Impact factor: 44.544

4.  Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

Authors:  Hagop M Kantarjian; Xavier G Thomas; Anna Dmoszynska; Agnieszka Wierzbowska; Grzegorz Mazur; Jiri Mayer; Jyh-Pyng Gau; Wen-Chien Chou; Rena Buckstein; Jaroslav Cermak; Ching-Yuan Kuo; Albert Oriol; Farhad Ravandi; Stefan Faderl; Jacques Delaunay; Daniel Lysák; Mark Minden; Christopher Arthur
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

5.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

Review 6.  Acute myeloid leukemia and myelodysplastic syndromes in older patients.

Authors:  Elihu Estey
Journal:  J Clin Oncol       Date:  2007-05-10       Impact factor: 44.544

7.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.

Authors:  Omar Abdel-Wahab; Ann Mullally; Cyrus Hedvat; Guillermo Garcia-Manero; Jay Patel; Martha Wadleigh; Sebastien Malinge; JinJuan Yao; Outi Kilpivaara; Rukhmi Bhat; Kety Huberman; Sabrena Thomas; Igor Dolgalev; Adriana Heguy; Elisabeth Paietta; Michelle M Le Beau; Miloslav Beran; Martin S Tallman; Benjamin L Ebert; Hagop M Kantarjian; Richard M Stone; D Gary Gilliland; John D Crispino; Ross L Levine
Journal:  Blood       Date:  2009-05-06       Impact factor: 22.113

8.  Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry.

Authors:  Gunnar Juliusson; Petar Antunovic; Asa Derolf; Sören Lehmann; Lars Möllgård; Dick Stockelberg; Ulf Tidefelt; Anders Wahlin; Martin Höglund
Journal:  Blood       Date:  2008-11-13       Impact factor: 22.113

9.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

10.  The prognostic significance of IDH2 mutations in AML depends on the location of the mutation.

Authors:  Claire L Green; Catherine M Evans; Lu Zhao; Robert K Hills; Alan K Burnett; David C Linch; Rosemary E Gale
Journal:  Blood       Date:  2011-05-19       Impact factor: 25.476
View more
  21 in total

1.  Getting personal with myelodysplastic syndromes: is now the right time?

Authors:  Nora Chokr; Alexander B Pine; Jan Philipp Bewersdorf; Rory M Shallis; Maximilian Stahl; Amer M Zeidan
Journal:  Expert Rev Hematol       Date:  2019-04-12       Impact factor: 2.929

2.  Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.

Authors:  Catherine C Coombs; David A Sallman; Sean M Devlin; Shweta Dixit; Abhinita Mohanty; Kristina Knapp; Najla H Al Ali; Jeffrey E Lancet; Alan F List; Rami S Komrokji; Eric Padron; Maria E Arcila; Virginia M Klimek; Marcel R M van den Brink; Martin S Tallman; Ross L Levine; Raajit K Rampal; Franck Rapaport
Journal:  Haematologica       Date:  2016-07-14       Impact factor: 9.941

Review 3.  Hypomethylating Agents as a Therapy for AML.

Authors:  Claude Gardin; Hervé Dombret
Journal:  Curr Hematol Malig Rep       Date:  2017-02       Impact factor: 3.952

Review 4.  Epigenetics in the hematologic malignancies.

Authors:  Chun Yew Fong; Jessica Morison; Mark A Dawson
Journal:  Haematologica       Date:  2014-12       Impact factor: 9.941

5.  A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia.

Authors:  Kirk E Cahill; Yasmin H Karimi; Theodore G Karrison; Nitin Jain; Margaret Green; Howard Weiner; Noreen Fulton; Sabah Kadri; Lucy A Godley; Andrew S Artz; Hongtao Liu; Michael J Thirman; Michelle M Le Beau; Megan E McNerney; Jeremy Segal; Richard A Larson; Wendy Stock; Olatoyosi Odenike
Journal:  Blood Adv       Date:  2020-02-25

Review 6.  Management of Newly Diagnosed Acute Myeloid Leukemia in the Elderly: Current Strategies and Future Directions.

Authors:  David Sanford; Farhad Ravandi
Journal:  Drugs Aging       Date:  2015-12       Impact factor: 3.923

7.  TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  John S Welch; Allegra A Petti; Christopher A Miller; Catrina C Fronick; Michelle O'Laughlin; Robert S Fulton; Richard K Wilson; Jack D Baty; Eric J Duncavage; Bevan Tandon; Yi-Shan Lee; Lukas D Wartman; Geoffrey L Uy; Armin Ghobadi; Michael H Tomasson; Iskra Pusic; Rizwan Romee; Todd A Fehniger; Keith E Stockerl-Goldstein; Ravi Vij; Stephen T Oh; Camille N Abboud; Amanda F Cashen; Mark A Schroeder; Meagan A Jacoby; Sharon E Heath; Kierstin Luber; Megan R Janke; Andrew Hantel; Niloufer Khan; Madina J Sukhanova; Randall W Knoebel; Wendy Stock; Timothy A Graubert; Matthew J Walter; Peter Westervelt; Daniel C Link; John F DiPersio; Timothy J Ley
Journal:  N Engl J Med       Date:  2016-11-24       Impact factor: 91.245

8.  Low Plasma Citrate Levels and Specific Transcriptional Signatures Associated with Quiescence of CD34+ Progenitors Predict Azacitidine Therapy Failure in MDS/AML Patients.

Authors:  Pavla Koralkova; Monika Belickova; David Kundrat; Michaela Dostalova Merkerova; Zdenek Krejcik; Katarina Szikszai; Monika Kaisrlikova; Jitka Vesela; Pavla Vyhlidalova; Jan Stetka; Alzbeta Hlavackova; Jiri Suttnar; Patrik Flodr; Jan Stritesky; Anna Jonasova; Jaroslav Cermak; Vladimir Divoky
Journal:  Cancers (Basel)       Date:  2021-04-30       Impact factor: 6.639

9.  DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.

Authors:  Heidi L Casellas Román; Kartika Venugopal; Yang Feng; Daniil E Shabashvili; Luisa M Posada; Jianping Li; Olga A Guryanova
Journal:  Leuk Res       Date:  2020-05-13       Impact factor: 3.156

Review 10.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Authors:  A P Im; A R Sehgal; M P Carroll; B D Smith; A Tefferi; D E Johnson; M Boyiadzis
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 12.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.